All News

Investigators Weigh Differences in Biosimilar Quality Reporting

January 23, 2021

Deana Ferreri, PhD

Article

Consistency of reporting quality attributes for biosimilars may differ, complicating the job of getting a full picture of biosimilarity.

The Top 5 Biosimilar Articles for the Week of January 18

January 22, 2021

Video

Here are the top 5 biosimilar articles for the week of January 18, 2021.

Coherus CEO Discusses Post–COVID-19 Growth Prospects

January 21, 2021

Tony Hagen

Article

Coherus BioSciences CEO Dennis M. Lanfear discusses the company's biosimilar marketing prospects in 2021.

Prestige Biopharma Plots Biosimilar Growth Strategy

January 20, 2021

Tony Hagen

Article

Biosimilars will be the cornerstone for a leap into biologics development and commercialization, according to the CEO of Prestige Biopharma. Also, Innovent Biologics reaches a marketing agreement.

Poll: Which of the following is true about insulin products and the BPCIA?

January 20, 2021

Article

Many patient advocates hope that expansion of the Biologics Price Competition and Innovation Act (BPCIA) will bring further competition to the insulin market—and lower prices.

Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab

January 19, 2021

Tony Hagen

Article

The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18, 2021

Tony Hagen

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.

IGBA, Celltrion, Others Mark Biosimilar Advances

January 17, 2021

Tony Hagen

Article

The Center for Biosimilars® reports on developments at the International Generic and Biosimilar Medicines Association (IGBA), Celltrion, Innovent Biologics, and Kamada.

Opinion: Is the Ophthalmology Market Ready to Embrace Biosimilars?

January 16, 2021

Sonia T. Oskouei, PharmD, BCMAS, DPLA

Article

Samsung Bioepis has filed for FDA approval for a ranibizumab biosimilar candidate (SB11), and more ophthalmology biosimilars are in the pipeline.

With New Policy, CMS Promises to Exit "Stone Age" of Health Information

January 15, 2021

Tony Hagen

Article

CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.

x